Haleon plc (LSE: HLN)
Health Care · Pharmaceuticals · GB
£3.70
+1.85% today · +3.4% 1Y
Haleon plc (LSE: HLN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $44.44B and employs 24,535 people.
Over the last twelve months the share price has gained 3.4%, trading between 2.74 and 4.16.
Tweenvest scores Haleon plc across four factors: quality 63/100, value 64/100, growth 45/100, dividend 64/100. Its strongest factor is value.
HLN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $44.44B
- Revenue (TTM)
- $14.80B
- P/E
- 20.42
- EPS
- 0.18
- Dividend yield
- 2.01%
- Beta (5Y)
- 0.25
- 52-week high
- £4.16
- 52-week low
- £2.74
- Avg volume (3M)
- —
- Shares outstanding
- 8.81B
- Employees
- 24,535
- Next earnings
- —
About Haleon plc
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
- ISIN
- GB00BMX86B70
- Founded
- 1715
- Listed since
- Jul 18, 2022
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,254.83 | +0.63% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.91 | -0.41% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $153.37 | +1.80% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.00 | +0.16% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £122.60 | +1.24% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.11 | +0.50% |
Figures last refreshed Aug 18, 2026.